In addition to the V600E (BRAF), K57N/E/T (MEK), and E545K/G/A (PI3K) mutations (Figure 6B–D), our analysis revealed other driver mutations such as N581, L505, G469A/V, and K601ER38H/C in the BRAF gene; P471, P124, E203K, F53L/V, and E102_I103del in the MEK gene; and H1047R, R357L/Q, G118D, and E726 in the PI3K gene driving growth signaling and survival pathways in CRC, melanoma, breast cancer, and other solid tumors [39,40]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.